Synthesised to the highest purity standards. Each vial verified by mass spectrometry and HPLC analysis. For qualified researchers only.
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide comprising 15 amino acids, originally isolated from the cytoprotective fraction of human gastric juice. Its sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — is not found in any naturally occurring protein and confers exceptional stability in biological fluids compared to other peptides of similar length.
Mechanism of Action. BPC-157 exerts its effects through multiple converging pathways. It upregulates growth hormone receptor (GHR) expression in tendon fibroblasts, modulates nitric oxide (NO) synthesis, and activates the FAK-paxillin pathway to accelerate cytoskeletal reorganisation during wound healing. It also interacts with the dopaminergic and serotonergic systems, which underpins the neuroprotective and mood-stabilising observations seen in rodent models.
Research Background. Over 80 peer-reviewed preclinical studies have examined BPC-157 across models of musculoskeletal injury, gastrointestinal damage, nerve lesion, and systemic inflammation. Key findings include accelerated tendon-to-bone healing in Achilles and rotator cuff models, reversal of NSAID- and alcohol-induced gastric ulceration, and significant neuroprotective effects in traumatic brain injury and spinal cord transection models. The compound has not progressed to human clinical trials as of the current literature, meaning all findings remain preclinical.
Typical Research Protocols. Published rodent studies commonly reconstitute BPC-157 in sterile bacteriostatic water or 0.9% saline at concentrations of 0.1–10 µg/kg body weight, administered intraperitoneally or subcutaneously. The 10mg vial format is suited to multi-experiment or dose-response study designs where precise serial dilution is required.
Supplied by Matrix Health. Each vial contains 10mg of BPC-157 as a lyophilised white powder, verified at ≥99% purity by HPLC and confirmed by mass spectrometry. Certificate of Analysis available on request. Store at −20°C; stable for 24 months lyophilised, or up to 4 weeks in solution at 4°C.
Powered by Stripe · SSL encrypted · All major cards accepted
Tendon & Ligament Repair: Multiple studies demonstrate accelerated tendon-to-bone healing. Shown to upregulate growth hormone receptor expression in fibroblasts.
Gastrointestinal Protection: Derived from a gastric protein, BPC-157 exhibits cytoprotective properties along the GI tract including ulcer healing in preclinical models.
Neuroprotective Properties: Rat models show protective effects against traumatic brain injury, with potential dopaminergic and serotonergic modulation.
Anti-inflammatory Signalling: Demonstrated inhibition of pro-inflammatory cytokines and modulation of nitric oxide pathways in preclinical inflammation models.
TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein encoded by the TMSB4X gene and found at high concentrations in platelets, wound fluid, and most nucleated cells. The synthetic fragment studied most extensively corresponds to the actin-binding domain of the native protein, conferring its primary biological activity while offering greater aqueous stability and batch-to-batch consistency than recombinant Tβ4 preparations.
Mechanism of Action. TB-500’s central mechanism is sequestration of G-actin (monomeric actin) via its LKKTET motif, modulating the G-actin/F-actin equilibrium within cells. This cytoskeletal remodelling underpins several downstream effects: accelerated cell migration of keratinocytes, endothelial cells, and fibroblasts to wound sites; upregulation of matrix metalloproteinases for extracellular matrix remodelling; and promotion of angiogenesis through VEGF pathway activation. It also exhibits anti-inflammatory activity by downregulating NF-κB signalling, reducing pro-inflammatory cytokines including TNF-α and IL-1β.
Research Background. Over 60 peer-reviewed preclinical studies have investigated TB-500 across models of dermal wound healing, tendon and ligament repair, cardiac injury, and neurological damage. Key findings include significantly accelerated full-thickness wound closure in rodent models, reduced infarct size and improved cardiac function following experimental myocardial infarction, and promotion of axonal regrowth in spinal cord injury models. Like BPC-157, TB-500 has not entered human clinical trials; all findings remain preclinical as of the current literature.
Typical Research Protocols. Published rodent studies typically reconstitute TB-500 in sterile bacteriostatic water or PBS at concentrations ranging from 1–5 mg/kg body weight, administered subcutaneously. The 10mg lyophilised vial format supports serial dilution for dose-response experiments or multi-timepoint study designs. Researchers frequently co-administer TB-500 with BPC-157 to explore synergistic tissue-repair effects across musculoskeletal and GI models.
Supplied by Matrix Health. Each vial contains 10mg of TB-500 as a lyophilised white powder, verified at ≥99% purity by HPLC and confirmed by mass spectrometry. Certificate of Analysis available on request. Store at −20°C; stable for 24 months lyophilised, or up to 4 weeks in solution at 4°C.
Powered by Stripe · SSL encrypted · All major cards accepted
IN STOCK